Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ezekowitz

Showing results (681-690 of 842) with videos related to

Pageof 85
Sort By:
Circulation|January 9, 2020
OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B)D Ian Paterson, George Wells, Fernanda Erthal, et al.
European Heart Journal|September 4, 2014
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillationRiccardo Cappato, Michael D Ezekowitz, Allan L Klein, et al.
American Heart Journal|March 25, 2014
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryEmily C O'Brien, DaJuanicia N Holmes, Jack E Ansell, et al.
JACC. Heart Failure|May 3, 2023
Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIAJaved Butler, Yinggan Zheng, Muhammad Shahzeb Khan, et al.
European Heart Journal|February 6, 2016
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2Hans-Christoph Diener, James Aisenberg, Jack Ansell, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 8, 2017
Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHFGad Cotter, Beth A Davison, Javed Butler, et al.
Lancet (London, England)|August 13, 2016
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort studyJeff S Healey, Jonas Oldgren, Michael Ezekowitz, et al.
European Heart Journal|February 6, 2016
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1Hans-Christoph Diener, James Aisenberg, Jack Ansell, et al.
Journal of the American College of Cardiology|August 2, 2023
Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3Stephen J Greene, Johann Bauersachs, Jasper J Brugts, et al.
Circulation|August 25, 2021
Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)Justin A Ezekowitz, Yinggan Zheng, Alain Cohen-Solal, et al.
Pageof 85

Showing results (681-690 of 842) with videos related to

Sort By:
Pageof 85
Circulation|January 9, 2020
OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B)D Ian Paterson, George Wells, Fernanda Erthal, et al.
European Heart Journal|September 4, 2014
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillationRiccardo Cappato, Michael D Ezekowitz, Allan L Klein, et al.
American Heart Journal|March 25, 2014
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryEmily C O'Brien, DaJuanicia N Holmes, Jack E Ansell, et al.
JACC. Heart Failure|May 3, 2023
Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIAJaved Butler, Yinggan Zheng, Muhammad Shahzeb Khan, et al.
European Heart Journal|February 6, 2016
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2Hans-Christoph Diener, James Aisenberg, Jack Ansell, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 8, 2017
Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHFGad Cotter, Beth A Davison, Javed Butler, et al.
Lancet (London, England)|August 13, 2016
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort studyJeff S Healey, Jonas Oldgren, Michael Ezekowitz, et al.
European Heart Journal|February 6, 2016
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1Hans-Christoph Diener, James Aisenberg, Jack Ansell, et al.
Journal of the American College of Cardiology|August 2, 2023
Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3Stephen J Greene, Johann Bauersachs, Jasper J Brugts, et al.
Circulation|August 25, 2021
Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)Justin A Ezekowitz, Yinggan Zheng, Alain Cohen-Solal, et al.
Pageof 85